Literature DB >> 21871939

In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization.

Qinjian Zhao1, Victoria Towne, Martha Brown, Yang Wang, Dicky Abraham, C Brent Oswald, Juan A Gimenez, Michael W Washabaugh, Ronald Kennedy, Robert D Sitrin.   

Abstract

Recombinant Hepatitis B surface antigen virus-like particles (VLPs) produced in yeast undergo spontaneous maturation during the vaccine production process, and the biophysical characteristics of the particles with respect to maturation were described in Zhao et al. (2006) [13]. Here we report additional biochemical and immunochemical characterization by various techniques, including the use of a panel of monoclonal antibodies (mAbs) that differ in their selectivity and conformation-sensitivity, for probing surface epitope structures. Crosslinking via interchain disulfide formation and binding of conformational specific antibodies in the mature particles were shown to be progressively enhanced. We show that redox-mediated VLP maturation is superior to heat-induced maturation in terms of generating VLPs which exhibit more complete crosslinking (>95%) and 2- to 3-fold higher antigenicity as defined by conformational antibodies. Therefore, the resulting VLPs from redox treatment resemble more closely their plasma-derived counterparts. The value of using multiple mAbs for probing surface epitopes was clearly demonstrated as different mAbs showed different degrees of sensitivity to the structural changes during HBsAg VLP maturation. The rapid, label-free technology of surface plasmon resonance performed at a single antigen concentration was shown to correlate well with a sandwich ELISA using parallel line analysis, currently implemented for product release and stability testing of RECOMBIVAX HB(®). Surface plasmon resonance offers both convenience and flexibility; multiple mAbs can be tested one at a time in the same set of experiments, providing a means to assess changes to individual epitopes. Taken together, these quantitative analytical tools enable more rapid, in-depth, and comprehensive process monitoring, process optimization, and assessment of product consistency and stability.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871939     DOI: 10.1016/j.vaccine.2011.08.070

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.

Authors:  Yue Zhang; Min Li; Fan Yang; Yufang Li; Zizheng Zheng; Xiao Zhang; Qingshan Lin; Ying Wang; Shaowei Li; Ningshao Xia; Jun Zhang; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform.

Authors:  John R Gallagher; Udana Torian; Dustin M McCraw; Audray K Harris
Journal:  Virology       Date:  2017-01-03       Impact factor: 3.616

Review 4.  The development of a recombinant hepatitis E vaccine HEV 239.

Authors:  Shao-Wei Li; Qinjian Zhao; Ting Wu; Shu Chen; Jun Zhang; Ning-Shao Xia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen.

Authors:  Yibin Zhu; Tianying Zhang; Jinghua Zhao; Zusen Weng; Quan Yuan; Shaowei Li; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

6.  Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.

Authors:  Qinjian Zhao; Yorgo Modis; Katrina High; Victoria Towne; Yuan Meng; Yang Wang; Jaime Alexandroff; Martha Brown; Bridget Carragher; Clinton S Potter; Dicky Abraham; Dave Wohlpart; Mike Kosinski; Mike W Washabaugh; Robert D Sitrin
Journal:  Virol J       Date:  2012-02-22       Impact factor: 4.099

7.  Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.

Authors:  Anke M Mulder; Bridget Carragher; Victoria Towne; Yuan Meng; Yang Wang; Lance Dieter; Clinton S Potter; Michael W Washabaugh; Robert D Sitrin; Qinjian Zhao
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

Review 8.  Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.

Authors:  Joan Kha-Tu Ho; Beena Jeevan-Raj; Hans-Jürgen Netter
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048

Review 9.  Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation.

Authors:  Yike Li; Xiaofen Huang; Zhigang Zhang; Shaowei Li; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Viruses       Date:  2020-01-16       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.